BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 25764124)

  • 1. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.
    Salci KR; Lee JH; Laronde S; Dingwall S; Kushwah R; Fiebig-Comyn A; Leber B; Foley R; Dal Cin A; Bhatia M
    Stem Cells; 2015 Jun; 33(6):1839-49. PubMed ID: 25764124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation.
    Hoffmann D; Göhring G; Heuser M; Ganser A; Schambach A; Morgan MA
    Stem Cells; 2016 Mar; 34(3):797-9. PubMed ID: 26388310
    [No Abstract]   [Full Text] [Related]  

  • 3. Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations.
    Lee JH; Salci KR; Reid JC; Orlando L; Tanasijevic B; Shapovalova Z; Bhatia M
    Stem Cells; 2017 Sep; 35(9):2095-2102. PubMed ID: 28758276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming of Acute Myeloid Leukemia Patients Cells: Harboring Cancer Mutations Requires Targeting of AML Hierarchy.
    Golubeva D; Porras DP; Doyle M; Reid JC; Tanasijevic B; Boyd AL; Vojnits K; Elrafie A; Qiao A; Bhatia M
    Stem Cells Transl Med; 2023 Jun; 12(6):334-354. PubMed ID: 37226319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
    Chao MP; Gentles AJ; Chatterjee S; Lan F; Reinisch A; Corces MR; Xavy S; Shen J; Haag D; Chanda S; Sinha R; Morganti RM; Nishimura T; Ameen M; Wu H; Wernig M; Wu JC; Majeti R
    Cell Stem Cell; 2017 Mar; 20(3):329-344.e7. PubMed ID: 28089908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells.
    Deslauriers AG; Kotini AG; Papapetrou EP
    Methods Mol Biol; 2021; 2185():411-422. PubMed ID: 33165864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of hematopoietic differentiation outcomes and molecular characterization reveals unbiased differentiation capacity and minor transcriptional memory in HPC/HSC-iPSCs.
    Gao S; Hou X; Jiang Y; Xu Z; Cai T; Chen J; Chang G
    Stem Cell Res Ther; 2017 Jan; 8(1):13. PubMed ID: 28114969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pluripotent cell models of fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors.
    Suzuki NM; Niwa A; Yabe M; Hira A; Okada C; Amano N; Watanabe A; Watanabe K; Heike T; Takata M; Nakahata T; Saito MK
    Stem Cells Transl Med; 2015 Apr; 4(4):333-8. PubMed ID: 25762002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.
    Kotini AG; Chang CJ; Chow A; Yuan H; Ho TC; Wang T; Vora S; Solovyov A; Husser C; Olszewska M; Teruya-Feldstein J; Perumal D; Klimek VM; Spyridonidis A; Rampal RK; Silverman L; Reddy EP; Papaemmanuil E; Parekh S; Greenbaum BD; Leslie CS; Kharas MG; Papapetrou EP
    Cell Stem Cell; 2017 Mar; 20(3):315-328.e7. PubMed ID: 28215825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid progenitors in remission bone marrow in patients with malignant blood diseases: clues for slow hematopoietic regeneration after ABMT?
    Hokland P; Nielsen B; Ellegaard J; Palshof T; Hokland M
    J Hematother; 1996 Jun; 5(3):279-88. PubMed ID: 8817395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A miRNA Signature in Human Cord Blood Stem and Progenitor Cells as Potential Biomarker of Specific Acute Myeloid Leukemia Subtypes.
    Cattaneo M; Pelosi E; Castelli G; Cerio AM; D'Angiò A; Porretti L; Rebulla P; Pavesi L; Russo G; Giordano A; Turri J; Cicconi L; Lo-Coco F; Testa U; Biunno I
    J Cell Physiol; 2015 Aug; 230(8):1770-80. PubMed ID: 25502508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling leukemia with pediatric acute leukemia patient-derived iPSCs.
    Li T; Zhang Y; Li Y; Wang X; Bao W; Huang J; Ma Y; Li S; Wang S; Yang Y; Liu Y; Gao Y; Feng H; Li Y
    Stem Cell Res; 2021 Jul; 54():102404. PubMed ID: 34111697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia.
    Dorantes-Acosta E; Chávez-González A; Santos JI; Medina-Sanson A; Mayani H
    Pediatr Blood Cancer; 2008 Dec; 51(6):741-6. PubMed ID: 18680148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts.
    Wierenga PK; Setroikromo R; Kamps G; Kampinga HH; Vellenga E
    Exp Hematol; 2003 May; 31(5):421-7. PubMed ID: 12763141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells.
    Geti I; Ormiston ML; Rouhani F; Toshner M; Movassagh M; Nichols J; Mansfield W; Southwood M; Bradley A; Rana AA; Vallier L; Morrell NW
    Stem Cells Transl Med; 2012 Dec; 1(12):855-65. PubMed ID: 23283547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell type of origin influences iPSC generation and differentiation to cells of the hematoendothelial lineage.
    Phetfong J; Supokawej A; Wattanapanitch M; Kheolamai P; U-Pratya Y; Issaragrisil S
    Cell Tissue Res; 2016 Jul; 365(1):101-12. PubMed ID: 26893154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of human β-thalassemia induced pluripotent cell lines by reprogramming of bone marrow-derived mesenchymal stromal cells using modified mRNA.
    Varela I; Karagiannidou A; Oikonomakis V; Tzetis M; Tzanoudaki M; Siapati EK; Vassilopoulos G; Graphakos S; Kanavakis E; Goussetis E
    Cell Reprogram; 2014 Dec; 16(6):447-55. PubMed ID: 25354259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy.
    Navarro S; Moleiro V; Molina-Estevez FJ; Lozano ML; Chinchon R; Almarza E; Quintana-Bustamante O; Mostoslavsky G; Maetzig T; Galla M; Heinz N; Schiedlmeier B; Torres Y; Modlich U; Samper E; Río P; Segovia JC; Raya A; Güenechea G; Izpisua-Belmonte JC; Bueren JA
    Stem Cells; 2014 Feb; 32(2):436-46. PubMed ID: 24420904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease.
    Son MY; Lee MO; Jeon H; Seol B; Kim JH; Chang JS; Cho YS
    Exp Mol Med; 2016 May; 48(5):e232. PubMed ID: 27174201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.